Cerenome to present interim clinical data from ReSPECT-LMM trial of REYOBIQ at SNO 2026

Cerenome, Inc. (Nasdaq: CNSY) announced it will present interim clinical data from its ReSPECT-LMM multidose study of REYOBIQ (rhenium Re186 obisbemeda) in leptomeningeal metastases at the Society for Neuro-Oncology 31st Annual Meeting and Education Day, scheduled for November 12-15, 2026.

Detected & updated continuously · Source: Nebula